Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2009 1
2010 1
2011 1
2012 1
2013 4
2015 1
2016 1
2017 4
2018 3
2020 4
2022 1
2023 3
2024 2
2025 3
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
The Past, Present, and Future of Non-Viral CAR T Cells.
Moretti A, Ponzo M, Nicolette CA, Tcherepanova IY, Biondi A, Magnani CF. Moretti A, et al. Among authors: magnani cf. Front Immunol. 2022 Jun 9;13:867013. doi: 10.3389/fimmu.2022.867013. eCollection 2022. Front Immunol. 2022. PMID: 35757746 Free PMC article. Review.
Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities.
Magnani CF, Gaipa G, Lussana F, Belotti D, Gritti G, Napolitano S, Matera G, Cabiati B, Buracchi C, Borleri G, Fazio G, Zaninelli S, Tettamanti S, Cesana S, Colombo V, Quaroni M, Cazzaniga G, Rovelli A, Biagi E, Galimberti S, Calabria A, Benedicenti F, Montini E, Ferrari S, Introna M, Balduzzi A, Valsecchi MG, Dastoli G, Rambaldi A, Biondi A. Magnani CF, et al. J Clin Invest. 2020 Nov 2;130(11):6021-6033. doi: 10.1172/JCI138473. J Clin Invest. 2020. PMID: 32780725 Free PMC article. Clinical Trial.
Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells.
Volta L, Myburgh R, Pellegrino C, Koch C, Maurer M, Manfredi F, Hofstetter M, Kaiser A, Schneiter F, Müller J, Buehler MM, De Luca R, Favalli N, Magnani CF, Schroeder T, Neri D, Manz MG. Volta L, et al. Among authors: magnani cf. Leukemia. 2024 Dec;38(12):2598-2613. doi: 10.1038/s41375-024-02409-1. Epub 2024 Sep 18. Leukemia. 2024. PMID: 39294295 Free PMC article.
Genome Editing in Engineered T Cells for Cancer Immunotherapy.
Bonini C, Chapuis AG, Hudecek M, Guedan S, Magnani C, Qasim W. Bonini C, et al. Among authors: magnani c. Hum Gene Ther. 2023 Sep;34(17-18):853-869. doi: 10.1089/hum.2023.128. Hum Gene Ther. 2023. PMID: 37694593 Free PMC article. Review.
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation.
Lussana F, Magnani CF, Galimberti S, Gritti G, Gaipa G, Belotti D, Cabiati B, Napolitano S, Ferrari S, Moretti A, Buracchi C, Borleri GM, Rambaldi B, Rizzuto G, Grassi A, Paganessi M, Meli C, Tettamanti S, Risca G, Pais G, Spinozzi G, Benedicenti F, Cazzaniga G, Capelli C, Gotti E, Introna M, Golay J, Montini E, Balduzzi A, Valsecchi MG, Dastoli G, Rambaldi A, Biondi A. Lussana F, et al. Among authors: magnani cf. Blood Cancer J. 2025 Apr 3;15(1):54. doi: 10.1038/s41408-025-01260-6. Blood Cancer J. 2025. PMID: 40180925 Free PMC article. Clinical Trial.
Acquisition of an immunosuppressive microenvironment after anti-CD19 CAR T-cell therapy is associated with T-cell dysfunction and resistance.
Ponzo M, Drufuca L, Buracchi C, Sindoni MM, Nucera S, Bugarin C, Bason R, Rossetti G, Bonnal R, Meli C, Rambaldi B, Lussana F, Ferrari S, Moretti A, Dastoli G, Risca G, Pellegrino C, Manz MG, Galimberti S, Rambaldi A, Gaipa G, Biondi A, Pagani M, Magnani CF. Ponzo M, et al. Among authors: magnani cf. J Immunother Cancer. 2025 Oct 23;13(10):e011768. doi: 10.1136/jitc-2025-011768. J Immunother Cancer. 2025. PMID: 41135951 Free PMC article.
32 results